search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
COAGULATION


n time-specific (eg 09:00, 13:00, 17:00…) n new vial QC: individual vial QC prior to sample analysis


n multi-vial QC: multiple vial QC for the same assay prior to sample analysis.


The CN-Series allows QC analysis both for current and new lots to be performed concurrently, making QC batch acceptance easier. The QC charts provide improved ease of navigation and accessibility of QC information. This is achieved with simple, rapid viewing, and export of information including user comments against individual data points. All reagent lot information is displayed in the QC chart. The same improvement process has been applied to the display of calibration information, making it easier to compare any of the 100 calibration curves against each assay, against one another. Linear one-stage factor assays on the CN-Series provide detection of factor activity down to <1 IU/dL. Multi-dilution analysis (MDA) allows maximisation of the measurement range without extrapolation of the calibration curve. In addition, reflex and re-analysis rules on the CN-Series provide automation to MDA assays using the appropriate dilution set. This complies with British2,3 and International4


guidelines to aid ®


Menu screen – QC charts can be customised into tabs for easy access to QC information and results. Analysis and Reagent Lot Group information is easily viewed for each QC data point.


detection of inhibitors and sample activation.


In the event of abnormal clotting


screen results, mixing studies are often the first reflex tests to be performed. The cross-mixing functionality on the CN-Series allows customisable plasma dilutions with normal pooled plasma. This supports the detection of clotting factor deficiencies or the presence of inhibitors, without the need for user intervention. International guidelines recommend the


use of mixing tests and the calculation of the Index of Circulating Anticoagulant (ICA).5


The CN-Series can calculate the ICA automatically when mixing studies are performed. The data are displayed in an easy-to-interpret format, both numerically and graphically, making the decision about the next appropriate test clearer. Clot waveform analysis (CWA) is an extended interrogation of the coagulation curve generated by the optical detection system during the measurement of the PT


ScheBo • SARS-CoV-2 Quick™ NEW!!


ANTIGEN TEST also available


E-mail:


covid@schebo.co.uk for details!


Ivor Smith, ScheBo • Biotech UK Ltd, PO Box 9459, Lyme Regis, DT6 9FL, U.K. Tel: 01256 477259 email: i.smith@schebo.co.uk www.schebo.co.uk


® WWW.PATHOLOGYINPRACTICE.COM DECEMBER 2020 41


DUAL


ANTIBODY TEST available now


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62